Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.
about
Beta-blockers for hypertensionBeta-blockers for hypertensionCalcium channel blockers versus other classes of drugs for hypertensionRe-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysisUse of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesThe 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyThe 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - TherapyBeta-blockers for hypertension.Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke of transient ischaemic attack (TIA) in primary care.Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model.Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial.The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall.Laboratory testing in newly treated elderly hypertensive patients without co-morbidities: a population-based cohort studyALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesValsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention."Later, lazier, and unluckier": a heuristic profile of high vulnerability is an independent predictor of uncontrolled blood pressure (the PREVIEW study)Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protectionManagement of essential hypertension.What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative studyCombinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study)Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.Management of Hypertension among Patients with Coronary Heart DiseaseEfficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.Sodium intake in men and potassium intake in women determine the prevalence of metabolic syndrome in Japanese hypertensive patients: OMEGA StudyNebivolol: a review.JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.Incidence and prognosis of resistant hypertension in hypertensive patients.Rebuttal: Do beta-blockers have a role in treating hypertension? YesThe role of existing and newer calcium channel blockers in the treatment of hypertension.Do beta-blockers have a role in treating hypertension? Yes.The paradigm has shifted to systolic blood pressure.Hypertension 2005: an evidence-based approach to diagnosis and treatment - an American perspective.Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention.Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA StudyCharacteristics and Factors Associated With Antihypertensive Medication Use in Patients Attending Peruvian Health FacilitiesWhy are we getting myocardial infarction? Because our genes date from the last Ice Age. The global cardiovascular risk.
P2860
Q24201511-C69C8D91-7DFB-45C5-8F13-1AA538C6C48EQ24202812-75D5924C-7414-400B-A37C-898D16209777Q24236584-7EA7BEB0-5F33-4C14-9235-D0950E734B9FQ24545775-0397E73B-FF11-4612-AE14-09D1BBA02B44Q24658205-C4CE5180-87A0-4676-A81E-9CBAD62DCEB1Q28211654-EB8A570A-B22C-4FB2-9D39-C2EFE7A80087Q28218811-C305C1DB-05BA-42E3-BDE8-9865C4108FE3Q30238911-C660F09E-341D-456B-B96D-0C79E8E6C1C9Q30496136-BC5C00DF-38E8-4031-AE19-B35801E6AED3Q30499940-47509447-C038-41B6-A45F-41FE613D11F0Q30543372-2A95276C-139E-4CC6-BBF0-718F4EBBFA77Q30574638-61132790-B15D-4BE7-B282-7CBB9B9531A0Q33239013-B2198514-FD8C-4CAC-9D04-DF343E962CD0Q33572877-C06F9B2D-81D0-4D91-8383-3BC2B2CD204CQ33576830-CCC11671-4060-45AC-8B50-CAB99F41E97CQ33715408-3234120E-6F9C-44FA-BF47-111219F0AA22Q34018990-4E9F2A4C-A6E2-46FD-98F1-41B44BC44A1FQ34041853-B52CF26F-5810-41E0-86BB-D0C0CF243541Q34068728-69162DAD-AC0F-4331-B03A-89627B391757Q34097871-2B2AB20B-E3CA-4248-A0F5-7B0DAC9D52B4Q34178297-33126E98-E52A-4E6E-809D-894D2553D84BQ34196851-C1E0AE1F-7E94-4090-A8A2-82A3F8D30505Q34724772-15366B90-574E-47AF-930E-5EC701D1F1B2Q34772940-82DB9C81-AD94-46A3-8C00-90C13FFDEEE5Q35113671-3E19400B-AA47-47B4-8934-7BE3B5FFC1DCQ35157962-91210F81-D96E-4FA7-8D83-CE923AC59FC8Q35669288-AAAEA021-9F06-417B-83FF-9DA1B9044475Q35753422-5D9BBB64-504D-4C2D-A746-46A0A14E024DQ35808362-EF171245-8EC0-4B9F-B67E-27DD0AFEC3B9Q35932321-008E405A-4F2C-4C73-91A4-724E9CDAA7A8Q35941880-907367FD-EB2A-4C91-99A0-6D50C5D70AF0Q35945719-4738C8E0-986A-414F-A8B9-D4509C9D77F5Q35951348-C44886F8-8601-4333-9D31-4A8BE4513E38Q35980993-040CEBC6-07D2-4F2A-8FC1-17566F30A1B5Q36216844-7732EE84-E4A3-4963-9D32-108958CC79A3Q36255428-D5FCDB21-5EBC-4541-9858-0EF92B754421Q36302833-94893FFA-D939-44F2-BA5A-2B3FD0A5DB51Q36317004-AD402C24-9CE6-4FC7-8ECA-39C21F4D6E3FQ36319161-80F04466-80C2-4EB2-AB9D-E4CB9DDD2862Q36362599-D944D6F8-A00E-424B-BEFF-20BD555D664A
P2860
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cardiovascular prevention and ...... ew updated until 1 March 2003.
@en
Cardiovascular prevention and ...... ew updated until 1 March 2003.
@nl
type
label
Cardiovascular prevention and ...... ew updated until 1 March 2003.
@en
Cardiovascular prevention and ...... ew updated until 1 March 2003.
@nl
prefLabel
Cardiovascular prevention and ...... ew updated until 1 March 2003.
@en
Cardiovascular prevention and ...... ew updated until 1 March 2003.
@nl
P1476
Cardiovascular prevention and ...... ew updated until 1 March 2003.
@en
P2093
Ji-Guang Wang
Lutgarde Thijs
P304
P356
10.1097/00004872-200306000-00002
P577
2003-06-01T00:00:00Z